Back to top
more

Nephros (NEPH)

(Delayed Data from NSDQ)

$2.14 USD

2.14
106

+0.05 (2.39%)

Updated Apr 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lantheus Holdings (LNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 14.29% and 6.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q1 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -53.85% and 25.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q4 Loss, Misses Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of -10% and 1.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q3 Loss, Tops Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0.00% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Nephros Inc. (NEPH) Report Negative Q2 Earnings? What You Should Know

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's What Could Help Nephros Inc. (NEPH) Maintain Its Recent Price Strength

Nephros Inc. (NEPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Nephros Inc. (NEPH) a Good Fit for "Trend Investing"

Nephros Inc. (NEPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Nephros Inc. (NEPH) Reports Q1 Loss, Tops Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 57.14% and 1.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q4 Loss, Tops Revenue Estimates

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 33.33% and 1.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Nephros Inc. (NEPH) Q4 Earnings Expected to Decline

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for August 31st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for August 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Chembio (CEMI) Jumps: Stock Rises 7.1%

Chembio (CEMI) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Nephros Sees Hammer Chart Pattern: Time to Buy?

Nephros has been struggling lately, but the selling pressure may be coming to an end soon.

OraSure Technologies (OSUR) in Focus: Stock Moves 7.6% Higher

OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Abbott (ABT) in Focus: Stock Moves 6.4% Higher

Abbott (ABT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Agios' IND for PKR Activator AG-946 Gets FDA Clearance

The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.

Nephros Sees Hammer Chart Pattern: Time to Buy?

Nephros has been struggling lately, but the selling pressure may be coming to an end soon.

Top Ranked Momentum Stocks to Buy for October 23rd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23rd